检索结果-南通市图书馆

First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma:A prospective,single-arm trial

引用

Asian Pacific Journal of Tropical Medicine 2022年第6期15卷 266-273页

作者： Xin Sun Ranxin Zhang Jie Xu Lu Xie Wei Guo Musculoskeletal Tumor Center Peking University People’s HospitalBeijing 100044China

Objective:To examine the efficacy and safety of anlotinib as first-line therapy to treat locally advanced or metastatic soft-tissue ***:This is a single-arm ***-naïve patients(≥14 years)with locally advanced or metastatic soft tissue sarcoma were *** treatment cycle lasted for 3 weeks,and included liposomal doxorubicin(40-50 mg/m^(2))on day 1 and anlotinib(12 mg)on days *** from the 9th cycle,treatment consisted of only *** continued until disease progression or intolerable *** primary efficacy end point was progression-free survival(PFS).Results:Eight patients were enrolled between July 25,2019 and January 8,*** median number of treatment cycles was *** 5.9 months median follow-up,PFS events occurred in 4(4/8,50%)*** median PFS was 11.3 months and the 6-month PFS rate was 56%.No patients attained complete response and 2 patients(fibrosarcoma,1 patient and undifferentiated pleomorphic sarcoma,1 patient)achieved partial *** patients(fibrosarcoma,2 patients and synovial sarcoma,1 patient)had stable *** objective response rate was 25%(2/8)for the study population,and the disease control rate was 75%(6/8).No new safety concerns ***:Anlotinib plus liposomal doxorubicin demonstrated antitumor activities in previously untreated locally advanced or metastatic soft tissue *** to the small sample size,further investigations with a larger population should be undertaken to confirm the study findings.

关键词： Soft-tissue sarcoma multikinase inhibitor Anlotinib Antiangiogenesis Liposomal doxorubicin Progression-free survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib

引用

World Journal of Gastrointestinal Oncology 2020年第3期12卷 301-310页

作者： Vincenzo Ricci Cristina Granetto Antonella Falletta Matteo Paccagnella Andrea Abbona Elena Fea Teresa Fabozzi Cristiana Lo Nigro Marco Carlo Merlano Medical Oncology and Laboratory of Translational Oncology Oncology DepartmentS.Croce and Carle Teaching Hospital CuneoCuneo 12100Italy Arco Cuneo Foundation Cuneo 12100Italy Medical Oncology S.G.Bosco HospitalTorino 10154Italy S.Croce and Carle Teaching Hospital Cuneo Cuneo 12100Italy

BACKGROUND Regorafenib is an oral small-molecule multikinase inhibitor approved in third or later line of treatment for patients with metastatic colorectal cancer(mCRC).Regorafenib has shown significant benefits in overall survival and progression free survival in two phase III trials compared to placebo in patients with mCRC who had progressed on previous *** To identify an immune profile that might specifically correlate with the outcome in patients treated with *** Blood samples were collected from 17 patients before treatment with regorafenib and from 6 healthy *** proteins evaluated(TNF-α,TGF-β,VEGF,CCL-2,CCL-4,and CCL-5)were selected on the basis of their roles in angiogenesis and colorectal cancer *** We found that TNF-αbasal level was significantly higher in mCRC patients compared to healthy *** Responder(NR)patients showing progression of disease(n=12)had higher basal level of TGF-β,TNF-α,VEGF,CCL-2 and CCL-5 compared to Responder(R)patients(complete response CR,n=1;partial response PR,n=1;Stable Disease SD,n=3).On the contrary,plasma basal level of CCL-4 was higher in R compared to NR *** values of TGF-βand TNF-αnegatively correlated with progression free *** These results suggest a cytokine signature potentially able to discriminate between R and NR patients to treatment with regorafenib.

关键词： Colorectal cancer multikinase inhibitor Cytokines Angiogenesis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：